ACM
HAE icon

Altalis Capital Management’s Haemonetics HAE Stock Holding History

Altalis Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-88,055
Closed -$3.54M – 14
2016
Q4 		$3.54M Sell
88,055
-16,702
-16% -$630K 3.97% 9
2016
Q3 		$3.79M Sell
104,757
-107,095
-51% -$3.68M 4.11% 8
2016
Q2 		$6.14M Buy
+211,852
New +$6.4M 4.4% 10

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Altalis Capital Management's HAE Position: Q1 2017 in Review

Altalis Capital Management sold out of Haemonetics (HAE) in Q1 2017, closing a stake of 88,055 shares — an estimated $3.54M sold.

Altalis Capital Management first reported a position in HAE in Q2 2016 and held it in 3 quarters. The position peaked at $6.14M in Q2 2016. 181 funds tracked by Wall St. Rank hold HAE as of Q1 2017.

  • Altalis Capital Management reported no remaining Haemonetics position as of Q1 2017 after selling out during the quarter.
  • Altalis Capital Management sold 88,055 Haemonetics shares in Q1 2017, an estimated $3.54M.
  • Altalis Capital Management first reported a position in Haemonetics in Q2 2016 and held it in 3 quarters.
  • Altalis Capital Management's Haemonetics position peaked at $6.14M in Q2 2016.
  • 181 funds tracked by Wall St. Rank held Haemonetics as of Q1 2017.

Based on Altalis Capital Management's 13F filing for Q1 2017, filed 15 May 2017.